AbbVie | ABBV - Interest Expense On Debt


AbbVie reported $645M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 299M 231M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
J&J USD 43M 25M Mar/2026
Medtronic USD 176M 5M Mar/2026
Merck USD 525M 46M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
UCB EUR 49M 29M Dec/2025
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
United Therapeutics USD 2.9M 200K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zoetis USD 61M 1000K Jun/2026